Amgen's better Neulasta news no consolation to Coherus

13 June 2017
biosimilars_samples_large

USA-based Coherus BioSciences (Nasdaq: CHRS) lost 24.5% of its value on Monday after receiving a complete response letter (CRL) from the US Food and Drug Administration (FDA) relating to its biosimilar version of Amgen’s (Nasdaq: AMGN) Neulasta (pegfilgrastim).

It was welcome news for Amgen on a day when the US biotech major saw the Supreme Court rule against its argument that biosimilar manufacturers should be forced to delay their 180-day marketing notices until after the FDA has approved their marketing applications.

"Neulasta is the largest-selling oncology biologic in the USA, and we anticipate CHS-1701’s approval will generate significant healthcare savings while increasing access"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars